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Abstract
Mitogen activated protein kinases (MAPKs) including Erk, Jnk and p38 regulate diverse cellular 
functions, and are thought to be controlled by independent upstream activation cascades. Here we 
show that the sestrins bind to and co-ordinate simultaneous Erk, Jnk and p38 MAPK activation in 
T lymphocytes within a new immune-inhibitory complex (sestrin-MAPK Activation Complex; 
sMAC). Whereas sestrin ablation resulted in broad reconstitution of immune function in stressed T 
cells, inhibition of individual MAPKs only allowed partial functional recovery. T cells from old 
humans and mice were more likely to form the sMAC, and disruption of this complex restored 
antigen-specific functional responses in these cells. Correspondingly, sestrin deficiency or 
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simultaneous inhibition of all three MAPKs enhanced vaccine responsiveness in old mice. Thus, 
disruption of sMAC provides a foundation for rejuvenating immunity during ageing.
Ageing is associated with a substantial decline in immune function that manifests as 
increased incidence of infection and malignancy and decreased responsiveness to 
vaccination 1,2. Given the worldwide demographic shift towards an older age 3, it is 
essential to understand mechanisms involved with age-related decline of immunity and 
identify strategies for restoring immune function. Recent studies suggest causative links 
between immunesenescence, metabolism and ageing and reveal that some of the age-
associated decline in immune function may be reversible 4–8. However, how the myriad of 
functional defects simultaneously appear in individual aged cells remains largely unknown.
Human T cells that exhibit multiple features of senescence increase during ageing 9. There 
is a sequential loss of the costimulatory receptors CD27 and CD28 as T cells progress 
towards senescence 10. Early-stage T cells within the CD4 compartment are CD27+CD28+, 
those at an intermendiate stage are CD27-CD28+, while the senescent T cell population is 
CD27-CD28- 5.
Mitogen activated protein kinases (MAPKs) are signal transducing enzymes involved in 
diverse aspects of mammalian physiology, including senescence, ageing and metabolism 11. 
Three main subgroups of MAPKs have been identified: Erk, Jnk and p38 12. Given the 
broad functions they control and the existence of independent upstream activation cascades, 
it is thought that each MAPK subgroup is separately regulated within individual cells 12–14. 
The possibility that all three MAPK subgroups may be co-ordinately controlled within a 
single cell-type has remained unexplored.
Sestrins, the mammalian products of the Sesn1, Sesn2 and Sesn3 genes 15–17, are a family 
of poorly understood stress sensing proteins, that lack obvious catalytic domains and 
stimulate the activation of AMPK by an as yet unknown mechanism while inhibiting 
mTORC1 signalling 18. AMPK is a heterotrimeric protein consisting of the catalytic α 
subunit and the regulatory β and γ subunits that are activated in response to increased 
intracellular AMP/ATP ratio 19. Sestrins have been proposed to inhibit mTORC1 signalling 
through both AMPK-dependent and independent pathways that involve formation of a 
complex with the RAGA/B GTPases 18,20–25. Due to their mTORC1 inhibitory activity, 
various anti-ageing functions have been ascribed to both the mammalian sestrins and their 
Drosophila counterpart, dSesn 20. However, a possible role of sestrins in the control of the 
immune response has not been determined.
In this study, we found that sestrins exhibit pro-ageing activities in T lymphocytes. We 
identified a sestrin-dependent MAPK activation complex (named sMAC hereafter) in these 
cells, within which the sestrins simultaneously coordinate the activation of Erk, Jnk and p38. 
Once activated, each MAPK was found to control a unique functional response. Disruption 
of the sMAC restored antigen-specific proliferation and cytokine production in T cells from 
old humans and enhanced responsiveness to influenza vaccination in old mice.
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Results
Sestrins are broad regulators of T cell senescence
The sestrins exhibit anti-ageing properties in muscle 20 but the immune related functions of 
these molecules have not been studied. We examined the expression of sestrin1, sestrin2 and 
sestrin3 proteins in blood-derived primary human CD4+ T cells from young donors (<40 
years old) defined as CD27+CD28+ non-senescent T cells (called Terl hereafter), 
CD27-CD28+ intermediate T cells (Tint) and CD27-CD28-CD4+ senescent T cells (Tsen) as 
described 5. CD4+ Tsen cells expressed significantly higher amounts of sestrin1, sestrin2 and 
sestrin3 proteins than Terl and Tint populations (Fig. 1a,b). We probed the function of 
endogenous sestrin proteins by transducing activated Tsen cells with lentiviral vectors co-
expressing a green fluorescent protein (GFP) reporter gene and inhibitory shRNAs to the 
SESN1 (shSesn1), SESN2 (shSesn2) or SESN3 (shSesn3) genes. A non-silencing shRNA 
lentiviral vector was used as a control (shCtrl) (Supplementary Fig. 1a-c). Transduction of 
shSesn1, shSesn2 or shSesn3 in Tsen cells resulted in broad functional reversal of 
senescence, including enhanced cell proliferation (Fig. 1c) and telomerase activity (Fig. 1d), 
diminished DNA damage foci (Fig. 1e), re-expression of the TCR signalosome components 
Lck and Zap70 (Fig. 1f and data not shown) and of the co-stimulatory receptors CD27 and 
CD28 (Fig. 1g) compared to shCtrl transduction. This enhancement of functionality in CD4+ 
Tsen cells was accompanied by restored calcium flux (Fig. 1h) and IL-2 synthesis (Fig. 1i). 
Therefore, in contrast to their well documented anti-ageing properties in invertebrates20,26, 
the sestrins induced multiple characteristics of senescence in T cells.
Sestrins bind to and activate Erk, Jnk and p38 MAPKs in Tsen cells
In Drosophila, mouse liver homogenates and human embryonic kidney 293 cell lines, sestrin 
function, including their anti-ageing effects, is largely mTORC1-dependent 20,21,23–
25,27,28. We found that CD4+ Tsen cells lacked the expression of both mTOR and its 
downstream effector kinase S6K1 (Supplementary Fig. 1d). Transduction of shSesn1, 
shSesn2 or shSesn3 in CD4+ Tsen cells restored both mTOR expression and downstream 
S6K1 activation compared to shCtrl (Supplementary Fig. 1e). However, sestrin-knocked-
down CD4+ Tsen cells maintained significantly enhanced calcium flux (Supplementary Fig. 
1f), IL2 synthesis (Supplementary Fig. 1g), telomerase activity (Supplementary Fig. 1h) and 
clearance of DNA damage foci (Supplementary Fig. 1i) even in the presence of rapamycin, 
an mTOR inhibitor, compared to sestrin-knocked down CD4+ Tsen cells growth in the 
absence of rapamycin . This indicates an mTORC1-independent mechanism of sestrin 
action.
To identify pro-senescence pathways of sestrin action, we immunoprecipitated sestrin1 from 
blood-derived, unstimulated CD4+ Tsen cells using an irrelevant IgG antibody as control. 
Sestrin1 immunoprecipitates were enriched for phosphorylated Erk, Jnk and p38 MAPKs 12 
compared to IgG immunoprecipitation (Fig. 2a). AMPK also precipitated with sestrin1 (Fig. 
2a). Similarly, sestrin2 co-immunoprecipitated with phosphorylated Erk, Jnk and p38 
MAPKs in CD4+ Tsen cells (Supplementary Fig. 2a). This suggests the existence of an 
endogenous supramolecular sestrin-dependent MAPK activation complex (sMAC), 
composed of sestrins and phosphorylated AMPK and Erk and Jnk and p38 MAPKs.
Lanna et al. Page 3
Nat Immunol. Author manuscript; available in PMC 2017 July 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Next we measured spontaneous Erk, Jnk and p38 MAPK activation in blood-derived Terl 
cells, Tint cells and Tsen cells within the CD4+ subset. Endogenous MAPK activation was 
enhanced in Tsen cells compared to Terl or Tint subsets (Supplementary Fig. 2b). To 
investigate canonical MAPK activators, we probed lysates from Terl, Tint and Tsen subsets 
directly ex vivo with antibodies to MKK7 (activator of Jnk), MKK4 (activator of Jnk and/or 
p38) and phosphorylated MEKK1/2 (activator of ERK). Tsen cells did not express or 
endogenously activate any upstream MKK4, MKK7 or MEKK1/2 molecules 
(Supplementary Fig. 2c). We next transfected siRNAs to MEKK1, MKK7 and MKK4 in Terl 
and Tsen subsets and measured Erk, Jnk and p38 phosphorylation in both cell types by 
phospho-flow technology. An irrelevant scrambled siRNA was used as control 
(Supplementary Fig. 2d). Compared to control transfection, silencing MEKK1, MKK7 and 
MKK4 inhibited Erk, Jnk and p38 phosphorylation in Terl cells, respectively. In contrast, 
Erk, Jnk and p38 phosphorylation were not affected in Tsen cells (Supplementary Fig. 2e). 
Thus, endogenous MAPK phosphorylation in Tsen cells took place in the absence of 
upstream canonical MAPK signalling 11.
We next investigated whether sestrins are non-canonical regulators of MAPK function. In 
vitro kinase assays demonstrated disrupted MAPK phosphorylation in AMPK 
immunoprecipitates from CD4+ Tsen cells transduced with shSesn vectors compared to 
shCtrl (Fig. 2b). However, treatment of triple sestrin-silenced T cells with the selective 
AMPK agonist A-76966229 for 1 hour reconstituted MAPK activation to levels detected per 
shCtrl transduction (Fig. 2b). We then transduced shAMPK5 and shCtrl vectors in CD4+ 
Tsen cells, immunoprecipitated sestrin2, and performed in vitro MAPK assays. MAPK 
phosphorylation was reduced in sestrin2 immunoprecipitates from shAMPK transduced-
CD4+ Tsen cells compared to shCtrl (Fig. S2f). Thus, sestrins promoted MAPK activation 
via AMPK.
Because the Thr-x-Tyr activation loop of MAPK proteins is not a direct AMPK substrate5, 
we investigated whether sestrin-bound MAPKs undergo AMPK-dependent auto-
phosphorylation. Adding exogenous ATP to sestrin1 immunoprecipitates from CD4+ Tsen 
cells strongly enhanced MAPKs phosphorylation in response to incubation with the AMPK 
agonist A-769662 compared to unstimulated reactions (Fig. 2c). The ATP-competitive Erk 
inhibitor FR18024, the JNK inhibitor SP-600125 or the p38 inhibitor SB-203580 impeded 
AMPK agonist-driven MAPK phosphorylation (Fig. 2c). Thus, individual MAPK activities 
were required for sMAC activation. Furthermore, MAPK auto-phosphorylation was 
triggered by activation of AMPK.
We next tested whether sestrins modulated MAPK signaling promoting ATP removal from 
the γ subunit of AMPK28. We therefore transduced CD4+ Tsen cells with shSesn vectors 
either individually or together, then immunoprecipitated AMPKγ, and measured ATP 
content by ELISA. This progressive single, dual or triple down-regulation of sestrin proteins 
induced a sestrin-dependent increase in the ATP content of AMPK-γ immunoprecipitates 
from CD4+ Tsen cells compared to shCtrl transduction (Fig. 2d). Likewise, the 
phosphorylation of AMPK-α, the catalytic subunit of the enzyme, was inhibited in extracts 
from triple sestrin-knocked-down CD4+ Tsen cells compared to shCtrl transduction (Fig. 2e). 
In addition, when we transfected siRNA to AMPK-γ in CD4+ Tsen cells (Supplementary 
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Fig. 2f) and immunoprecipitated sestrin1, we found reduced Erk, Jnk and p38 MAPK 
presence in the sestrin1 complex compared to siCtrl transfection (Fig. 2F). Thus, sestrins 
regulate Erk, Jnk and p38 MAPK auto-phosphorylation by fine-tuning AMPK-γ ATP 
loading.
Recombinant sestrins reconstitute the sMAC in Terl cells
We performed ‘in vitro reconstitution’ experiments using lysates from CD4+ (Terl cells), 
which do not express endogenous sestrin proteins. We transfected siAMPK-γ or siCtrl into 
Terl cells that were lysed and immunoprecipitated with AMPK-α antibodies 36h later. We 
then added either recombinant sestrin1/2/3 or GFP proteins and measured Erk, Jnk and p38 
phosphorylation. The addition of sestrins triggered a dose-dependent activation of AMPK-
associated MAPKs in lysates from siCtrl-transfected CD4+ Terl cells compared to addition 
of recombinant GFP protein (Fig. 3a). In contrast, siAMPK-γ-transfection in CD4+ Terl cells 
prevented sestrin-driven MAPK activation (Fig. 3a). MAPK recruitment to AMPK was not 
significantly altered by recombinant sestrins in these in vitro reconstitution assays (Fig. 3b). 
These data suggest that sestrins coordinated the sMAC upstream of AMPK-γ and that all 
MAPKs were bound to AMPK in their inactive form.
To study whether the sMAC formed as a unique complex, we added all three Sestrins to 
lysates of blood-derived primary human CD4+ Terl cells, then analysed sestrin2 
immunoprecipitates using gel-filtration chromatography. Under native conditions, the sMAC 
eluted with an estimated molecular mass of about 1000 kDA (Fig. 3c), while the sestrin-
mTORC1 inhibitory complex, which is known to contain GATOR2 and RAGA/B 23–25, 
was 660 kDA (Fig. 3c). Similar size endogenous complexes were eluted from lysates 
obtained from CD4+ Terl cells that had been glucose starved for 12 hours 5 and 
immunoprecipitated with sestrin2 (not shown), indicating that physiological stress stimuli 
also triggered the formation of two sestrin-containing complexes of different sizes, 
controlling either mTORC1 or MAPK activities in primary human Terl cells.
To determine the physiological impact of endogenous sMAC formation in CD4+ Terl cells, 
we transduced these cells with either all three shSesn1/shSesn2/shSesn3 or shCtrl 
lentivectors and exposed them to irradiation to induce a stress-response. Sestrin expression 
was up-regulated in Terl cells after irradiation (Supplementary Fig. 3a). Importantly, Erk, Jnk 
and p38 phosphorylation was strongly induced upon irradiation in shCtrl-transduced CD4+ 
Terl cells compared to triple-sestrin-silenced CD4+ Terl cells (Fig. 3d). Notably, triple 
sestrin-knockdown in irradiated CD4+ Terl cells preserved telomerase activity 
(Supplementary Fig. 3b) and IL-2 production compared to irradiated shCtrl-transduction 
(Supplementary Fig. 3c). Sestrin-silenced-Terl cells also showed reduced irradiation-
triggered DNA damage (Supplementary Fig. 3d), indicating that sestrin expression was 
required for induction of senescence in stressed T cells.
Individual MAPKs control distinct aspects of T cell senescence
Because all three MAPKs were activated in the sMAC following AMPK-activation, we 
investigated the role of each MAPK in this complex. We treated CD4+ Tsen with the Erk 
inhibitor FR18024, the Jnk inhibitor SP-600125 or the p38 inhibitor SB-203580 for 36h 
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before immunoprecipitating sestrin1 and measuring Erk, Jnk, and p38 phosphorylation. 
Endogenous MAPK phosphorylation of sestrin1-associated MAPKs was inhibited in 
MAPKi-treated CD4+ Tsen cells compared to DMSO treatment (Supplementary Fig. 4a). In 
these experiments, blocking any MAPK restored the CD3 and rhIL-2-induced proliferation 
of CD4+ Tsen cells to a similar extent, by 2- to 2.5-fold, compared to DMSO vehicle 
(Supplementary Fig. 4b). However, only inhibition of p38, but not inhibition of Jnk or Erk, 
enhanced telomerase activity in CD3/rhIL-2-activated CD4+ Tsen cells compared to DMSO 
(Fig. 4a), as previously reported 4,5,30. Conversely, blocking Erk, but not p38 or Jnk 
activation, decreased endogenous DNA damage foci in CD3/rhIL-2-activated CD4+ Tsen 
cells (Fig. 4b). Finally, blocking Jnk, but not p38 or Erk activation reconstituted the 
expression of both the key TCR signalosome component Lck in CD4+ Tsen cells compared 
to DMSO treatment (Fig. 4c), and that of the co-stimulatory receptor CD28 (not shown). 
Similar results were obtained when Erk, p38 and Jnk were individually silenced in CD4+ 
Tsen cells (Supplementary Fig. 4c-d). Thus, while MAPKs activation promoted T cell 
senescence, each MAPK regulated unique functional hallmarks of the senescence 
programme.
Next we incubated sestrin2-shRNA-transduced CD4+ Tsen cells with the AMPK agonist 
A-769662, which activates AMPK independently of sestrins (Supplementary Fig. 4e) 
followed by treatment with siRNAs specific for either Erk, p38 and Jnk for 48 hours. 
Sestrin2 knock down in Tsen cells enhanced telomerase activity (Fig. 4d), T cell activation as 
measured by increased calcium flux (Fig. 4e) and decreased formation of DNA damage foci 
(Fig. 4f) compared to shCtrl transduction. However the agonist-induced activation of AMPK 
reversed these functional changes (Fig. 4d-f), suggesting that the sestrins act via AMPK to 
inhibit functional responses in CD4+ Tsen cells. Importantly, transfection of siRNAs to either 
p38, Jnk or Erk in AMPK agonist-treated, sestrin2-knocked-down CD4+ Tsen cells restored 
telomerase activity and TCR activation and reduced DNA damage foci, respectively (Fig. 
4d-f). Similar observations were made when silencing sestrin1 in CD4+ Tsen cells (Fig. S4f). 
Thus, each MAPK in the sMAC controlled different aspects of T cell senescence 
downstream of a common sestrin trigger.
Enhanced sMAC formation with age
We investigated whether the sestrins preferentially modulate T cell function in older 
humans. We found up to a 10-fold increase in sestrin expression in total CD4+ T cells from 
older subjects (70-85 years) compared to younger subjects (20-35 years) (Fig. 5a). Increased 
sestrin expression was most pronounced within the CD4+ Tsen cells from old compared to 
young individuals (Fig. 5b). We did not detect sMAC in CD4+ Terl cells from younger 
individuals by image-stream analysis (Fig. 5c and Supplementary Fig. 8a) while sestrin2 co-
localized with p-Erk, p-Jnk and p-p38 in CD4+ Tsen isolated from the same subjects (Fig. 
5c). In contrast, both CD4+ Tsen and Terl cells from older humans showed sestrin2 and p-
MAPK co-localization, especially in the CD4+ Tsen subset (Fig. 5c). Single cell analysis of 
co-localization scores of sestrin2 and p-MAPKs showed an age-dependent increase in sMAC 
formation (Fig. 5d). This identifies enhanced formation of the sMAC in human T cells 
during ageing.
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Shingles is caused by the re-activation of varicella zoster virus (VZV) and the incidence of 
this disease increases during ageing 31,32. In both young (20-35 years) and old (70-85 
years) individuals, the CD4+ Terl cells showed higher proliferative activity in response to 
VZV antigen activation than the CD4+ Tsen population (Fig. 5e). In addition, the 
proliferation of both subsets was lower in old compared to young individuals (Fig. 5e). 
ShRNA-mediated silencing of sestrin1 in CD4+ Tsen cells from old donors significantly 
enhanced their proliferation (Fig. 5f) and IL-2 synthesis (Fig. 5g) after VZV activation 
compared to shCtrl transduction, especially at low antigen dose and when transducing 
shSesn2 and shSesn3 in addition to shSesn1 (Fig. 5f-g). Similar results were obtained with 
cytomegalovirus (CMV)-specific T cell responses from old humans (Supplementary Fig. 5a-
b). Therefore, silencing of sestrin expression in primary T cell populations from old humans 
enhanced antigen-specific proliferation and cytokine production in vitro.
Sestrin deficiency enhances responsiveness to vaccination in old mice
CD4+ T cells from 20-month old mice showed increased expression of sestrin1, sestrin2 and 
sestrin3 proteins compared to those from 2-month old animals (Supplementary Fig. 6a). We 
investigated the response to influenza vaccination in aged-matched Sesn1+/- and Sesn1-/- 
mice. The Sesn1-/- animals did not express sestrin1 (Supplementary Fig. 6b). These mice 
were co-housed for 20 months and challenged subcutaneously with FLUAD, a clinically 
approved trivalent inactivated influenza vaccine that is also effective in rodents 33. Saline 
injection served as control. After five days, Sesn1-/- but not Sesn1+/- mice exhibited 
splenomegaly (Supplementary Fig. 6c) and a three-fold increase in splenocytes after 
vaccination (Fig. 6a). Correspondingly, there was a 2-fold increase in the frequencies of 
splenic CD4+ and CD8+ T cells in vaccinated Sesn1-/- mice compared to vaccinated Sesn1+/- 
mice (Fig. 6b and Supplementary Fig. 6d). The frequency of myeloid and NK cells were 
also increased in vaccinated Sesn1-/- mice compared to controls by 5 and 2-fold respectively 
(Supplementary Fig. 6e,f). Within the CD4+ T cell compartment, there was a 2-fold 
expansion of CD62L-CD44+ T effector cells and a corresponding contraction of the 
CD62L+CD44- naïve T cell population from vaccinated Sesn1-/- mice compared to 
vaccinated Sesn1-/+ controls (Supplementary Fig. 6g). These differences in T cell 
frequencies between genotypes were not evident before vaccination (not shown). 
Functionally, Sesn1-/- CD4+ T cells exhibited increased IL-2 and IFN-γ production and 
enhanced proliferation compared to vaccinated Sesn1-/+ controls after vaccination (Fig. 
6d,e). Therefore, sestrin deficiency enhances T cell responsiveness and also the expansion of 
innate cells during ageing in vivo.
To investigate whether enhanced T cell responsiveness after vaccination was antigen-
specific, we re-challenged Sesn1+/- or Sesn1-/- T cells with Sesn1+/- antigen presenting cells 
(APCs) pulsed with FLUAD in vitro. There was increased IFN-γ and IL-2 synthesis by 
Sesn1-/-, compared to Sesn1+/- CD4+ T cells (Fig. 6f and data not shown). In addition, 
siRNA-mediated silencing of sestrin2 in Sesn1-/- null CD4+ T cells further increased their 
responsiveness to Sesn1+/- APCs pulsed with FLUAD (Fig. 6f).
When measuring antibody titres, we found a 2-to-3-fold increase in influenza-specific 
circulating IgGs in Sesn1-/- compared to Sesn1+/- mice (Fig. 6g) and Sesn1-/- B cells showed 
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indeed enhanced IgG isotypic switch compared to Sesn1+/- mice after vaccination 
(Supplementary Fig. 6h). B cell frequencies, however, were slightly reduced in the spleen of 
vaccinated Sesn1-/- mice compared to vaccinated Sesn1+/- controls (not shown). The collated 
data on the increase in numbers of all cell types examined before and after vaccination are 
shown in Supplementary Fig. 6i. Thus, sestrin deficiency restored vaccine responsiveness 
during ageing in vivo.
MAPK inhibition phenocopies sestrin deficiency in vivo
We next measured Erk, Jnk and p38 phosphorylation in sestrin2+ CD4+ T cells which 
comprised up to 70% of the total CD4+ T cell pool (Fig. 7a) from 20-month old Sesn1-/+ and 
Sesn1-/- mice after FLUAD vaccination. Erk, Jnk and p38 phosphorylation was robust in 
sestrin2+ CD4+ T cells from Sesn1-/+ mice, and reduced in Sesn1-/- CD4+ T cells (Fig. 7b). 
Notably, reduced Erk, Jnk, and p38 phosphorylation and increased IFN-γ production 
correlated directly in sestrin2+ CD4+ T cells from vaccinated Sesn1-/- mice compared to 
vaccinated Sesn1-/+ mice (Fig. 7c). Sestrin1 deficiency did not affect Erk, Jnk and p38 
phosphorylation in the minor Sestrin2- CD4+ T cells compared to those from Sesn1-/+ mice 
(Supplementary Fig. 7a). To test whether inhibition of all MAPKs would boost vaccine 
responsiveness in aged mice, we administered the Erk inhibitor FR18024, the Jnk inhibitor 
SP-600125 and the p38 inhibitor SB-203580 by intra-peritoneal injection either individually 
or together to 16-month old mice vaccinated with FLUAD, and examined both the sestrin2+ 
CD4+ T cell and CD19+ B cell subsets. Mice treated with all three MAPK inhibitors 
developed splenomegaly (Fig. 7d and Supplementary Fig. 7b) and showed increased splenic 
CD4+ T cell numbers compared to DMSO vehicle controls or mice receiving the individual 
MAPK inhibitors after vaccination (Fig. 7e). MAPK self-phosphorylation was either 
selectively or globally inhibited in CD4+ T cells from mice treated with either individual 
MAPK inhibitors or all of them together respectively compared to DMSO (Fig. 7f). Triple, 
but not individual inhibition of MAPKs boosted IFN-γ synthesis in sestrin2+ CD4+ T cells 
following vaccination compared to DMSO-treatment (Fig. 7g). Triple MAPK inhibition also 
induced a 3-fold increase in the frequencies of sestrin2+ CD19+ B cells undergoing vaccine-
specific IgG-isotypic switch compared to DMSO, which was not observed when inhibiting 
individual MAPKs (Fig. 7g). In contrast, inhibition of MAPK signaling in both sestrin2- 
CD4+ T and CD19+ B cells reduced vaccine-induced IFN-γ production and IgG-isotypic 
switch, respectively (Supplementary Fig. 7c). Thus, disruption of all MAPK pathways in 
Sestrin2+ T and B cell populations enhanced vaccine responsiveness in old mice.
The sMAC is formed in mouse T cells
We isolated CD4+ T cells from Sesn1-/+ and Sesn1-/- mice, immunoprecipitated sestrin2, and 
investigated Erk, Jnk and p38 phosphorylation. Sestrin2 complexes from Sesn1-/- CD4+ T 
cells showed reduced p-Erk, p-Jnk and p-p38 than those from Sesn1-/+ CD4+ T cells (Fig. 
8a-b). Sestrin2-MAPK binding was not affected by sestrin1 deficiency (not shown). Image-
stream analysis confirmed disrupted sMAC activation in spleen-derived CD4+ T cells from 
Sesn1-/- mice compared to Sesn1+/- mice (Fig. 8c-d). In vitro kinase assays showed that 
incubation of sestrin2 immunoprecipitates from Sesn1-/- mouse CD4+ T cells with 
recombinant human sestrin1 protein reconstituted MAPK activation in lysates from these 
cells (Fig. 8e). This effect was not observed in sestrin2 immunoprecipitates from AMPK-γ 
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silenced CD4+ T cells compared with siCtrl transfection (Fig. 8e). The A-769662 agonist-
driven activation of AMPK also restored MAPK phosphorylation in sestrin2 
immunoprecipitates from splenic Sesn1-/- CD4+ T cells, compared to DMSO treatment, and 
was further enhanced by the addition of ATP, needed to fuel MAPK auto-phosphorylation 
(Fig. 8f). Thus, the sMAC was also formed and coordinated by the sestrins in mice.
Discussion
Here we show that in Tsen cells Erk, Jnk and p38 MAPK are simultaneously activated due to 
constitutive expression of sestrin proteins. In flies, sestrin expression increases upon 
maturation and ageing and triggers feedback anti-ageing pathways through a TORC1 
inhibitory complex 20. Similarly, in muscle, sestrins exhibit mTORC1-dependent anti-
ageing activities 22. We now describe an opposite pro-ageing function of sestrins in T cells 
that occurred independently of mTORC1, and instead was mediated by an Erk/Jnk/p38 
MAPK activation complex (sMAC). Such co-ordinated MAPK activation was previously 
unknown and is distinct from the canonical MAPK activation cascades where Erk, Jnk and 
p38 are regulated independently 11.
All regulatory elements within the sMAC interacted constitutively in Tsen cells. The sMAC 
was also distinct from the previously described sestrin-mTORC1 inhibitory complexes 
containing GATOR and RAG proteins 23–25, suggesting that the anti-ageing/pro-ageing 
dichotomy of sestrin action in T cells versus other cell types may depend on different 
sestrin-protein interactions. Consistently, mTORC1 inhibition has been strongly associated 
with longevity in both muscle and insects 34 while p38 MAPK activation can drive T cell 
ageing and senescence 4–6,30 . Sestrin may therefore exert anti- or pro-ageing effects 
through two different macromolecular complexes. Whether the sMAC also controls ageing 
in non-immune cells remains to be determined.
The sMAC also formed in Terl cells upon glucose deprivation (not shown), and this extends 
previous observations highlighting the convergence of both senescence and low-nutrient 
signals to regulate T cell function (‘Intra-sensory’ signalling) 5,9. When examining glucose 
deprived sestrin-silenced Terl cells, we also found disrupted AMPK phosphorylation and a 
transient increase in T cell activation followed by T cell death if glucose deprivation 
persisted (not shown). Sestrins may thus function as an energy-sensing ‘rheostat’ that 
directly binds to AMPK-γ and promotes AMPK activation to favour T cell survival at the 
expenses of function under severe stress.
The sMAC was larger than the sestrin-mTORC1 inhibitory complex, and additional 
unknown proteins may contribute to its regulation. p38 auto-phosphorylation was a feature 
of non-canonical MAPK activation in T cells which requires p38 binding to specific 
scaffolding molecules such as TAB1 5,35. We now show that sMAC coordinates the 
simultaneous activation of all MAPK pathways. However, TAB1 was not required for the 
activation of Jnk or Erk, while it mediated activation of p38 within the sMAC (not shown). 
We propose a model in which three separate MAPK sub-complexes are constitutively bound 
to AMPK in their inactive form. When expressed, sestrins would promote the unloading of 
ATP from AMPK-γ and activate the AMPK complex. In turn, this would trigger the auto-
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phosphorylation of all associated MAPKs. Distinct scaffolding molecules may be required to 
support the auto-phosphorylation of each of the 3 MAPKs in the sMAC.
Silencing of sestrin expression allowed a broad enhancement of T cell activity, whereas 
downstream targeting of any individual MAPK was much more selective. It is therefore 
possible to exert narrower or broader control over senescence-related T cell functional 
changes by targeting different molecules within the sMAC. Since each MAPK controlled 
different aspects of T cell senescence, they may have to be simultaneously targeted for 
effective immune boosting during ageing. However, direct inhibition of MAPKs may not be 
feasible for immunotherapy as it would negatively regulate the responses of T and B-
lymphocytes that do not express sestrins. On the other hand, inhibition of the sestrins would 
disrupt global MAPK signalling. This would spare sestrin-negative cells, in which MAPKs 
may be activated via canonical pathways 36 and may thus circumvent toxicity. A caveat to 
consider is that sestrin inhibition may enhance the proliferative activity of senescent cells 
that have residual DNA damage and therefore, prolonged inhibition of sestrins may result in 
malignancy 37. However, short-term inhibition of sestrins could be a beneficial 
immunotherapeutic strategy.
Methods
Human studies
We collected heparinized peripheral blood samples from 120 individuals (aged 20-85, male 
55% and female 45%). Samples from young (aged: 20-35) and old (aged: 65-80) donors 
were obtained with the approval of the Ethical Committee of Royal Free and University 
College Medical School and voluntary informed consent, in accordance with the Declaration 
of Helsinki. Donors did not have any co-morbidity, were not on any immunosuppressive 
drugs, and retained physical mobility and lifestyle independence.
Western Blot analysis
Lysates from 2 x 106 cells were used for Western Blot analysis. Endogenous signaling 
studies were assessed in ex vivo purified CD4+ CD27/CD28 T cell subsets as described 
previously5. Transduced CD4+ CD27- CD28- T cells were analyzed by immunoblotting one 
week after activation (see below). Membranes were probed with antibodies to: Sestrin1 
(Genetex; Abcam), Sestrin2 (Cell Signaling), Sestrin3 (Sigma), ERK, p-ERK, p-JNK, p-p38, 
AMPK-α, p-AMPK-α, mTOR S6K1, MKK7, MKK4, p-MEK1/2 and GAPDH (all from 
Cell Signaling).
Immunoprecipitation
For co-immunoprecipitation analysis, cell-lysates were prepared using ice-cold HNGT 
buffer (50 mM HEPES, pH 7.5, 150 mM EDTA, 10 mM sodium pyrophosphate, 100 mM 
sodium orthovanadate, 100 mM sodium fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 
and 1 mM phenylmethylsulfonyl fluoride). Lysates from 20 × 106 cells were used for 
immunoprecipitation analysis. For the minor CD4+ CD28− CD27− subset, cells from two 
separate individuals were pooled to obtain sufficient material for the assay. Extracts were 
incubated with the indicated antibodies at 4 °C on a rotary shaker overnight, followed by 
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incubation with protein A–G conjugated agarose beads (Santa Cruz Biotechnology) at 4 °C 
for 3 h. Samples were washed and analyzed by immunoblotting as indicated. Co-
immunoprecipitated proteins were detected using Mouse Anti-rabbit IgG Conformation 
Specific (L27A9; Cell Signalling) or Mouse Anti-rabbit IgG light chain, followed by a 
secondary anti-mouse IgG antibody (all from Cell Signalling) and ECL Prime Western 
detection kit (GE Healthcare).
In vitro binding assay
Briefly, lysates from CD4+ CD27+ CD28+ T cell were incubated with recombinant Sestrins 
for 1 hour, followed by phosphorylated or total AMPK immunoprecipitation. AMPK 
complexes were washed extensively and global MAPK activation was measured by 
immunoblotting or in vitro kinase assays (see below). Absolute MAPK binding was 
determined using ELISA-based total ERK, JNK and p38 detection assays according to the 
manufacturer’s instructions (Abcam; see below). In some experiments, absolute MAPK 
binding was determined on endogenous Sestrin immunoprecipitates from CD4+ CD27- 
CD28- T cells, 48h post-transfection. MAPK binding assays are shown as proportional to 
fold increase at 450 nm absorbance emission of triplicate wells ± s.e.m, and were 
normalized to the indicated ‘bait’ proteins i.e. Sestrin1 (MBS9327570) or AMPK-α 
(ab151280) used in the immunoprecipitation assay.
In vitro kinase assay
Sestrin or AMPK Immunoprecipitates were washed twice in lysis buffer and twice in kinase 
buffer (all from Cell Signaling). Kinase reactions were incubated for 30 min at 30 °C either 
in the absence or in the presence of 200 μM ATP (Cell Signaling), as indicated. MAPK 
activity was assessed using Phospho-Tracer ELISA Kits according to the manufacturer’s 
instructions (Abcam; see below). In some experiments, exogenous recombinant human 
Sestrin proteins (Genway; 1 μg/mL), the AMPK agonist A-769662 (150 μM), the Erk 
inhibitor FR18024 (20 μM); the Jnk inhibitor SP-600125, (10 μM); or the p38 inhibitor 
SB-203580, (10 μM) were added directly to the in vitro kinase reaction itself for 30’, as 
indicated. In vitro kinase assays are shown as proportional to fold increase at 450 nm 
absorbance emission of triplicate wells ± s.e.m, normalized to the total amounts of co-
immunoprecipitated MAPKs.
Detection of co-immunoprecipitated proteins by ELISA
Briefly, an antibody mix was prepared by adding Capture Antibody Reagent(s) to MAPKs 
and Detection Antibody Reagent (both provided with the Phospho Tracer kit by Abcam), in 
a 1:1 ratio, and 50 μl of this antibody mix were added to the in vitro kinase/binding reaction 
product (50 μl), loaded in the Phospho Tracer micro-plates. Antibody binding was then 
allowed for 1 hour at room temperature on a micro-plate shaker. Wells were rinsed three 
times with 200 μl of 1 X washing buffer (provided with the kit). Meanwhile, a substrate mix 
was prepared, immediately before use, by diluting 1:100 the HR-substrate 10-Acetyl-3, 7- 
dihydroxyphenoxazine (ADHP) with ADHP Dilution Buffer (both provided with the kit), a 
stabilized H2O2 solution. Next, 100 μl of this substrate mix were added to each well, and 
incubated 10’ at room temperature on a micro-plate shaker for colour development. The 
reaction of conversion of ADHP into the fluorescent molecule Resorufin was then stopped 
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by adding 10 μl of stop solution to each well. Signal was read using an Elisa reader micro-
plate. Background was calculated in parallel IgG control immunoprecipitation reactions.
Measurement of AMPK-γ ATP loading
T cell AMPK-γ 1 immunoprecipitates were analyzed for ATP content using an ATP 
determination kit, according to the manufacturer’s instructions (Life Technologies). Total 
AMPK-γ 1 immunoprecipitates were quantified by Elisa (LifeSpan Biosciences).
T cell activation dynamics
For detection of intracellular calcium, we used x-Rhod1, a visible light-excitable calcium 
chelator suitable for flow-cytometry. Briefly, transduced cells were incubated with this dye 
(2.5 μM, 37C; 20’) washed in indicator-free medium to eliminate unspecific binding, then 
incubated for further 30 mins to allow complete dye de-esterification, as instructed by the 
manufacturer (Molecular Probes, Invitrogen). Cells were then stimulated by aCD3 for 2 
mins immediately followed by flow-cytometry analysis. In experiments with ‘multi-layer’ 
modulation of signaling, stably-transduced primary human CD27- CD28- CD4+ T cells were 
activated with α-CD3 (0.5 μg/mL) and rh-IL2 (10 ng/mL) for 24 hours in the presence of the 
indicated siRNAs and/or the AMPK-activator A-769662 (150 μM) or the m-TORC1 
inhibitor rapamycin (20 ng/mL), followed by dye incubation, short-term re-activation and 
intracellular calcium detection, as above. IL-2 synthesis or release was analyzed by ELISA-
based or intra-cellular flow cytometry respectively, as indicated. Active cycling upon 
stimulation was further confirmed by staining for the proliferation-related antigen ki-67.
Lentiviral vector design
The pHIV1-SIREN-GFP system used for knockdown of gene expression possesses a U6-
shRNA cassette to drive shRNA expression and a GFP reporter gene which is controlled by 
a PGK promoter5. The following siRNA sequences were used for gene knockdowns: 
CCTAAGGTTAAGTCGCCCTCG (shCTRL), ATGATGTCAGATGGTGAATTT 
(shAMPKα), CCAGGACCAATGGTAGACAAA (shSesn1), 
CCGAAGAATGTACAACCTCTT (shSesn2) and CAGTTCTCTAGTGTCAAAGTT 
(shSesn3). The shAMPKα sequence was previously described and validated in primary 
human CD4+ T cells5. VSV-g pseudotyped lentiviral particles were produced, concentrated 
and titrated in HEK 293 cells as described38.
Cell cultures and lentiviral transduction of primary human T lymphocytes
Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 
100 U/ml penicillin, 100 mg/ml streptomycin, 50 μg/ml gentamicin, and 2 mM L-glutamine 
(all from Invitrogen) at 37°C in a humidified 5% CO2 incubator. Purified human highly 
differentiated CD4+ CD27- CD28- T cells were activated in the presence of plate-bound 
αCD3 Ab (purified OKT3, 0.5 μg/ml) plus rhIL-2 (R&D Systems, 10 ng/ml), and then 
transduced with pHIV1-Siren lentiviral particles (MOI=10) at 48 and 72 hours after 
activation. Non-senescent CD4+ CD27+ CD28+ T cells were cultured and transduced as 
above after activation by plate-bound αCD3 (0.5 μg/mL) plus αCD28 (0.5 μg/mL). When 
antigen specific responsiveness was assessed, CD27- CD28- CD4+ T cells were re-activated 
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10 days post-transduction using autologous antigen presenting cells (APCs) pre-loaded for 4 
hours with various dilutions of Varicella zoster virus lysates (Zeptometrix Corporation), as 
indicated. Antigen presenting cells were obtained by depleting CD3 positive cells from 
autologous, fresh PBMC preparations and cultured with transduced T cells, in a 3:1 ratio. 
Antigen-specific responses are shown as fold increase normalized to transduced cells before 
re-stimulation, with control cells set as 1, in triplicate experiments.
Transfections
Human or mouse primary CD4+ T cells were transfected with siRNAs to Erk, Jnk, p38, 
AMPK-γ, MEKK1, MEKK4, MEKK7 or an irrelevant control siRNA sequence (all from 
Santa Cruz Biotechnology) using Nucleofector Kit according to the supplier’s protocol 
(Amaxa, Lonza Walkersville; program V024), as indicated. Cells were then rested and 
analyzed 48 hours later for functional or signaling readouts.
Quantitative PCR (Real time analysis)
Four days post transduction, samples from 5 x 105 viable senescent CD4+ CD27- CD28- T 
cells were resuspended in TRIzol (Ambion). For cDNA synthesis, RNA was retro-
transcribed using M-MuLV Reverse Transcriptase (New England Biolab) and random 
primers. Relative transcript expression was normalized using the CT threshold cycle method 
according to the supplier’s protocol (Applied Biosystems).
Signaling studies
Cells were fixed with warm Cytofix Buffer (BD Biosciences) at 37°C for 10 min, 
permeabilized with ice-cold Perm Buffer III (BD Biosciences) at 4°C for 30 min and then 
incubated for 30 min at room temperature with antibodies to: LCK, ZAP-70, p-AMPK, 
Sestrin2 (all from Cell Signalling), PercPCy5-conjugated p-Erk, Alexa-Fluor 647-
conjugated p-Jnk, PE-conjugated p-p38 and PE-conjugated γ-H2A-x (all from BD 
Biosciences). When primary unconjugated antibodies were used, they were subsequently 
probed with a secondary mouse (or goat) Alexa Fluor 647-conjugated anti-rabbit IgG (BD 
Biosciences) for 30’ at room temperature, in the dark. After washing in Stain Buffer (BD 
Pharmingen), samples were analysed immediately using an LSR Fortessa (BD Biosciences). 
Data were analyzed using FlowJo software (Treestar). For transduced cells, events were 
gated on the GFP+ compartment as indicated.
Measurement of telomerase activity
Telomerase activity was determined using the TeloTAGGG telomerase ELISA kit from 
Roche according to the manufacturer's instructions from extracts of 2 x 103 viable CD4+ 
CD27- CD28- T cells. The absolute numbers of CD4+ CD27- CD28- T cells were 
enumerated by trypan blue (Sigma) and proliferation was determined by Ki67 staining as 
described 39. Telomerase activity is expressed as proportional to fold increase at 450 nm 
absorbance emission of triplicate wells ± s.e.m.
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Proliferation assays
Four days post transduction, proliferation of activated senescent human CD27- CD28- CD4+ 
T cells was assessed by overnight probing with [3H] thymidine and expressed as fold 
increase in [3H] thymidine incorporation (cpm) of triplicate wells ± s.e.m. Alternatively, 
antigen-specific responsiveness of senescent human CD27- CD28- CD4+ T cells was 
assessed by staining for the cell cycle related nuclear antigen Ki-67 four days post-activation 
with autologous VZV-pulsed APCs.
Mice
Sesn1-/- mice were generated from Sesn1+/- embryonic stem (ES) cells in the C57BL/6 
background, obtained from EUCOMM. These cells were created by targeted gene trap 
approach and contain reporter-tagged insertion within intron 5 of the Sesn1 gene with a 
strong splice acceptor site expressing a β-Gal-Neo fusion protein that disrupts the Sesn1 
ORF. The Sesn1+/- mice, produced from ES cells, were backcrossed again to wild-type 
C57BL/6 mice (n = 5) to eliminate any non-specific genetic aberrations that may present in 
the chromosomes from the ES cells. After the backcrossing, the Sesn1+/- mice were 
interbred to generate Sesn1-/- mice, which were found to be fully viable and fertile. Sesn1+/- 
littermates were used as a control strain, and co-housed with the Sesn1-/- mice throughout 
the course of aging experiments. The absence of Sestrin1 mRNA and protein was confirmed 
by RT-PCR and immunoblot analyses of splenocytes (Fig. S6) as well as other tissues (data 
not shown). Mice were maintained in filter-topped cages and were given free access to 
autoclaved chow diet and water, according to National Institutes of Health (NIH) and 
institutional guidelines. All animal ageing studies were overseen by the University 
Committee on Use and Care of Animals (UCUCA) at the University of Michigan.
Mouse studies
Age-matched (20 month-old) mice were imported from the University of Michigan, rested 
for 10 days, and then used for in vivo studies. Control Sesn1+/- and Sesn1-/- null mice were 
subcutaneously injected with the seasonal influenza vaccine FLUAD (Novartis; 1: 20 of the 
human dose). A saline solution (PBS) was used as control injection. Five days later, animals 
were euthanized in a CO2 chamber, spleens collected, and processed for splenocyte 
isolation. Mouse CD4+ T cells were obtained from splenocytes by immunomagnetic 
separation (Miltenyi Biotec) and immediately analyzed for phenotypic, signaling and 
functional profiles by either flow cytometry or Image-Stream, as indicated. CD4+ 
phenotypic analysis was performed by surface staining to CD62L and CD44. For recall-
responses, control Sesn1+/- and Sesn1-/- null CD4+ T cells were re-challenged with control 
Sesn1+/- APCs pre-loaded with FLUAD (1:100, 1:50 and 1:25 of the human dose), then 
IL-2+, IFN-γ+ or•ki67+ T cells were analyzed 18-hours later by flow-cytometry. All in vivo 
studies were undertaken at University College London in collaboration with Prof. Derek 
Gilroy (licence no. 70/7354).
Antibody titration
Sesn1+/- and Sesn1-/- mice were vaccinated with FLUAD as above described. One week 
later, mice were sacrificed and blood samples were immediately collected by cardiac 
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bleeding. Levels of circulating immunoglobulins (IgGs) were analyzed using a serum 
dilution of 1:200 in 0.1% non-fat dry milk 0.5% Tween-20/PBS, as described 33. Samples 
were incubated on Nunc Maxisorp plates pre-coated with FLUAD overnight (1:40; for 18 
hours at 4 °C), or PBS as background control. Plates were washed 3 times with 0.5% 
Tween-20/PBS and blocked with 200 μl of 4% non-fat dry milk (GE-Healthcare). Antigen-
specific serum antibodies were detected using horseradish peroxidase (HRP) conjugated 
antibodies (anti-mouse IgG, Sigma Aldrich) at 1:3000 dilution in 0.1% non-fat dry milk 
0.5% Tween-20/PBS, at room temperature. Substrate activity was detected using 100 μL of 
tetramethylbenzidine (TMB) substrate (BD Biosciences) and stopped using 50 μL 2N 
H2SO4 per well. Circulating vaccine-speciific IgG levels were determined by ELISA 
(absorbance emission at 450 nm) of triplicate wells ± s.e.m.
Inhibition of Sestrin-MAPK signaling in vivo
Aged-matched mice (16 months) were injected i.p. with the Erk inhibitor FR18024 (25 mg/
Kg); the Jnk inhibitor SP-600125 (16 mg/Kg); and the p38 inhibitor SB-203580 (10 mg/Kg) 
individually or with all 3 inhibitors together. Drug vehicle was DMSO. Three hours later, 
mice were vaccinated with FLUAD as above. Triple and individual MAPK inhibition 
treatments were then repeated daily. Five days later, mice were culled, spleens collected and 
the impact of in vivo blocking MAPK signaling on immune-responsiveness was analysed in 
Sestrin2+ T and B cell populations, as indicated.
Analysis of the Sestrin-MAPK signalling complex in vivo
Primary human or mouse CD4+ T cells were fixed with 2% paraformaldehyde, 
permeabilized with methanol and stained for Sestrin2, p-ERK, p-JNK and p-p38 direclty ex 
vivo, as above described. For human experiments, CD4+ T cells were separated into early-
differentiated and highly differentiated populations according to their relative CD27/CD28 
expression profile from either young (20-35 years) or old donors (70-85 years). All samples 
were run on an Amnis® Image Stream cytometer using INSPIRE® software, magnification 
60x. Data were analyzed using IDEAS® v.6.1 software (Amnis). Co-localization signals 
were determined on a single cell basis using Bright Detail Similarity (BDS) Score analysis. 
Co-localization was considered with BDS of ≥2.0.
Gel-Filtration Chromatography
A Superdex 200 (GE Healthcare) gel filtration column was first equilibrated with 1.5 CV of 
endotoxin free PBS (Hyclone) at room temperature. Sestrin2 complexes were injected at 
time 0 (500 ul) and eluted using a single isocratic wash, fractions collected, and analyzed by 
ELISA-based binding assays (absorbance at 450 nm) across the spectrum for the indicated 
proteins. Phosphorylated MAPKs were detected using Phospho-Tracer ELISA kits (Abcam) 
as above described. For detection of Mios (MBS9330396); RagA (MBS9334409); and RagB 
(MBS9318748). The column was calibrated with protein markers as described 18
Statistical analysis
Graphpad Prism was used to perform statistical analysis. For pairwise comparisons, a paired 
Student’s t-test was used. For three matched groups, a one-way analysis of variance 
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(ANOVA) for repeated measures with a Bonferroni post-test correction was used. *p<0.05 , 
**p<0.01 and ***p< 0.001 throughout. For correlation studies, Pearson correlation test.
Data availability
The data generated or analysed during this study are included in this published article and its 
supplementary information files. The data not shown can be obtained from the 
corresponding authors upon reasonable request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Sestrins are broad regulators of T cell senescence.
(a) Expression of surface CD27 and CD28 in human CD4+ T cells by flow-cytometry. (b) 
Immunoblots (left) and flow cytometry data (right) of endogenous sestrin1, sestrin2 and 
sestrin3 expression in CD4+ T cells gated as in (a). (c) 3H-thymidine uptake and (d) 
telomerase activity in CD4+ Tsen cells transduced as indicated. (e) DNA damage foci 
assessed by the DNA damage response marker γ-H2Ax in cells as above. Flow cytometry of 
(f) intracellular LCK, (g) CD27 and CD28 co-stimulatory receptors, (h) calcium abundance 
and (i) IL2 synthesis in CD4+ Tsen cells transduced as indicated. Results presented relative 
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to those of cells transduced with shCtrl, set as 1. Data are representative of four experiments 
(a, b (left)) or pooled from four experiments with four individual donors (b (right)) or three 
donors (c, d, e, f, g, h, i). **p<0.01 and ***p< 0.001 calculated using ANOVA for repeated 
measures with Bonferroni post-test correction. Error bars indicate s.e.m.
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Fig. 2. Sestrins bind to and activate Erk, Jnk and p38 in Tsen.
(a) Immunoblot analysis of lysates from CD4+ Tsen precipitated with IgG control or sestrin1 
antibodies, and stained for the indicated proteins. Right margin, molecular weights. (b) 
MAPK phosphorylation of AMPK immunoprecipitates from CD4+ Tsen transduced as 
indicated then treated with the AMPK agonist A-769662 (150 μM, 60’) 96h later. Results 
assessed by in vitro kinase assay based on an enzyme-linked immunosorbent assay 
(absorbance at 450 nm) and presented relative to that of cells transduced with shCtrl, set as 
1. (c) MAPK auto-phosphorylation in sestrin1 complexes from CD4+ Tsen incubated for 30’ 
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with the AMPK agonist A-769662 (150 μM, 30’), the Erk inhibitor FR18024 (20 μM), the 
Jnk inhibitor SP-600125 (10 μM) or the p38 inhibitor SB-203580 (10 μM), in the presence 
or absence of ATP (200 μM). MAPK activity was determined and presented as in (b). (d) 
ELISA-based ATP abundance in AMPK-γ immunoprecipitates from CD4+ Tsen whereby 
one or more sestrins were silenced by shRNA. Results presented relative to that of cells 
transduced with shCtrl, set as 1. (e) AMPK phosphorylation of cells as in (d); GAPDH, 
loading control. (f) Elisa-based MAPK-binding assays in sestrin1 immunoprecipitates from 
cells as in (a) transfected with either Ctrl or siAMPK-γ for 36h, and presented relative to 
those of cells transfected with siCtrl, set as 1. Data are representative of two (a) or three (e) 
experiments or pooled from three independent experiments with three individual donors (b, 
c, d, f). *p<0.05 **p<0.01 and ***p< 0.001, ANOVA for repeated measures with Bonferroni 
post-test correction. Error bars indicate s.e.m. throughout.
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Fig. 3. Reconstitution of the sMAC in Terl.
(a) ELISA-based MAPK phosphorylation in AMPK immunoprecipitates from CD4+ Terl 
cells transfected as indicated, lysed 36h later, and incubated with either GFP (‘no Sesn’) or 
recombinant human sestrins (1 μg/mL, each) for 1h. Sestrin-dependent MAPK activation 
presented relative to that of GFP-treated extracts (‘no Sesn’), set as 1. (b) ELISA-based 
MAPK binding in lysates from CD4+ Terl cells, incubated with recombinant sestrins for 1h 
followed by immunoprecipitation with AMPK antibodies. MAPK recruitment to AMPK 
presented relative to that of GFP-treated extracts (‘no Sesn’). (c) Gel-filtration 
chromatography coupled to ELISA-binding assays of sestrin2 complexes from CD4+ Terl 
cells after incubation with recombinant sestrins. d) Irradiation-triggered Erk, Jnk and p38 
phosphorylation in CD4+ Terl transduced as indicated, then analyzed by phospho-flow 8h 
after radiation. Data are pooled from three (a) or two (b,c,d) independent experiments. 
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*p<0.05 **p<0.01 and ***p< 0.001, ANOVA for repeated measures with Bonferroni post-
test correction. Error bars indicate s.e.m. throughout.
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Fig. 4. Individual MAPKs control different aspects of T cell senescence
Measurement of (a) telomerase activity, (b) endogenous DDR foci and (c) expression of the 
TCR signalosome component LCK in CD4+ Tsen cells treated with the Erk inhibitor 
FR18024 (20 μM), the Jnk inhibitor SP-600125 (10 μM) or the p38 inhibitor SB-203580 (10 
μM) for 36 hours, then analysed for functional readouts. A DMSO solution was used as 
control. (e-g) Effect of the indicated siRNAs on (d) telomerase activity, (e) calcium flux and 
(f) DDR foci in sestrin2-silenced CD4+ Tsen treated with the AMPK agonist A-769662 (150 
μM, 48 hours). Data pooled from four independent experiments with four individual donors 
(a, b, c) or three independent experiments (d, e, f), and presented relative to those of cells 
transfected or transduced with siCtrl or shCtrl, set as 1. **p<0.01 and ***p< 0.001, ANOVA 
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for repeated measures with Bonferroni post-test correction. Error bars indicate s.e.m. 
throughout.
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Fig. 5. Enhanced sMAC formation with age.
(a) Immunoblots (left) and data (right) of endogenous sestrin proteins in lysates from young 
(20-35 years) versus old (70-85 years) primary human CD4+ T cells. Age-dependent 
expression of sestrins was normalized to endogenous GAPDH and presented relative to that 
of young donors, set as 1. (b) Flow-cytometry assessing sestrin2+ cells among CD4+ Terl 
and CD4+ Tsen subsets from 8 young and 8 old individuals. (c) Age-dependent sMAC 
formation by Image Stream in cells as in (b); representative of several images from 4 
different individuals per each age-group. (d) Sestrin2+-p-MAPKs+ co-localization scores 
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(BDS) of cells as in (c) (n = 4). (e) VZV-specific proliferation in CD4+ Terl and CD4+ Tsen 
cells from 3 young and 3 old donors. Pooled data (n = 3) presented relative to those of CD4+ 
Terl from young donors, set as 1. (f) Restored VZV-specific sensitivity (proliferation) in 
CD4+ Tsen from old humans where one or two Sestrins were silenced by shRNA (n = 3), 
presented relative to that of cells transduced with shCtrl and stimulated with the lowest VZV 
antigen dilution (1:100), set as 1. (g) Restored IL2 synthesis in sestrin-silenced CD4+ Tsen 
reactivated with autologous APCs loaded with a VZV antigen dilution of 1:100 and 
presented as in (f) (n = 3). Data are pooled from three experiments with three separate 
donors (a, e, f, g) or four experiments with eight (b) or four (c, d) donors. *p<0.05 **p<0.01 
and ***p< 0.001, ANOVA for repeated measures with Bonferroni post-test correction. Error 
bars indicate s.e.m. throughout.
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Fig. 6. Sestrin deficiency enhances responsiveness to vaccination in old mice.
(a) Splenocyte count of 20-month Sesn1+/- and Sesn1-/- mice vaccinated with FLUAD (1:20 
of human dose) or vehicle saline solution, then culled 5 days later. (b) Absolute CD4+ T cell 
count in mice as in (a). (c) Frequencies of naïve CD62L+ CD44- and effector CD62L- 
CD44+ CD4+ T cells in Sesn1+/- and Sesn1-/- mice vaccinated with FLUAD. (d) Counter-
plots (left) and MFI data (right) showing IFN-γ and IL-2 production among CD4+ T cells 
from Sesn1+/- and Sesn1-/- mice after FLUAD-vaccination. Pooled results (n = 4) presented 
relative to those of vaccinated Sesn1+/- mice, set as 1. (e) Proliferation among CD4+ T cells 
Lanna et al. Page 29
Nat Immunol. Author manuscript; available in PMC 2017 July 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
from mice as in (d), representative overlay and pooled data (n = 4). (f) IFN-γ production in 
Sesn1+/- and Sesn1-/- CD4+ T cells after FLUAD-vaccination, transfected as indicated then 
re-stimulated for 18h with Sesn1+/- APCs pre-loaded with FLUAD. Results presented 
relative to that of vaccinated Sesn1+/- mice, set as 1. (g) One-week vaccine-specific IgG 
titers in serum of vaccinated Sesn1+/- or Sesn1-/- mice. ELISA-based binding assays 
presented relative to those of vaccinated Sesn1+/- mice, set as 1. Data are from two 
experiments with six (a, b) or four (c, d, e, g) individual aged-matched mice per group or 
three independent experiments with three individual mice per group (f). *p<0.05 **p<0.01 
and ***p< 0.001, ANOVA for repeated measures with Bonferroni post-test correction (a, b, 
c, f) or paired Student’s t-test (d, e, g). Error bars indicate s.e.m. throughout.
Lanna et al. Page 30
Nat Immunol. Author manuscript; available in PMC 2017 July 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 7. Simultaneous MAPKi phenocopies Sestrin-deficiency in vivo
(a) Phospho-flow analysis of sestrin2 expression in CD4+ T cells from 16-month old mice. 
(b) Erk, Jnk and p38 phosphorylation in CD4+ T cells from control Sesn1+/- and Sesn1-/- 
mice (20 months) vaccinated as in Figure 6. Data (n = 4) presented relative to those of 
control Sesn1+/- mice, set as 1. (c) Correlation between reduced sestrin2+-p-Erk+/p-Jnk+/p-
p38+ signaling and enhanced IFN-γ+ production in CD4+ T cells from Sesn1-/- versus 
Sesn1+/- mice after FLUAD vaccination (n = 4; r2 = 0.82). (d) Splenocyte and (e) CD4+ T 
cell counts from 16-old mice injected with Erk (25 mg/kg), Jnk (16 mg/kg) and p38 (10 
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mg/kg) inhibitors either individually or together (triple MAPKi), vaccinated with FLUAD, 
and daily kept on MAPKi for five days. Results relative to those of DMSO-treated mice, set 
as 1. (f) MAPK-self phosphorylation in CD4+ T cells from mice as in (d-e) assessed by in 
vitro kinase assays, and presented relative to those of DMSO treated mice, set as 1. (g) 
FLUAD-driven IFN-γ production and IgG isotypic-switch among sestrin2+ CD4+ T and 
CD19+ B cells in mice as in (d-e), assessed by flow-cytometry. Pooled data (n = 4) presented 
relative to those of DMSO treated mice, set as 1. Data are pooled from four experiments 
with four (age-matched) mice per group (a, b, c, d, e, g) or two experiments (f). **p<0.01 
and ***p< 0.001, ANOVA for repeated measures with Bonferroni post-test correction. Error 
bars indicate s.e.m. throughout. r2, Pearson-correlation test.
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Fig. 8. The sMAC is formed in mouse T cells.
(a) Immunoblot analysis and (b) pooled data (n = 4) of Erk, Jnk, and p38 phosphorylation in 
lysates from CD4+ T cells from 20-month old vaccinated Sesn1+/- and Sesn1-/- mice 
following immunoprecipitation with sestrin2 antibodies. Results in (b) presented relative to 
those of Sesn1+/- mice, set as 1. Sestrin2 expression in whole cell lysates (WCL), loading 
control. Sestrin1 expression is also shown. (c) Image-Stream analysis and (d) % co-
localization scores of sestrin2+-pMAPKs+ in CD4+ T cells from Sesn1-/- and Sesn1-/+ mice, 
five days post-vaccination with FLUAD, presented as in (b). In vitro MAPK assays of 
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sestrin2 immunoprecipitates from mouse Sesn1-/- CD4+ T cells incubated for 60’ with or 
without (e) recombinant human sestrin1 or (f) the AMPK agonist A-769662, in the presence 
or absence of ATP. Results presented relative to that of non-reconstituted Sesn1-/- cells 
(‘basal’), set as 1. In (e) cells were transfected with the indicated siRNAs 48h before lysis. 
Data are representative of four experiments (a, c) or pooled from four experiments with four 
(age-matched) individual mice (b, d, e, f). **p<0.01 and ***p< 0.001, ANOVA for repeated 
measures with Bonferroni post-test correction. Error bars indicate s.e.m. throughout.
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